1UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macro-vascular and microvascular complication in type 2 diabetes: UKPDS 38. Br Meal J 1998 ;S17; 703-713.
2Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259.
3Lewis EJ, Hunsicker LG, Bain PR, et al. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Eng J Med 1993;229:1456-1462.
4Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes on patients with type 2 diabetes and nephropathy. N Engl J Meal 2001 ; 345 : 861-869.
5Lewis E J, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathydue to type 2 diabetes, N Engl J Med 2001;345 : 851 - 860.
6Nilsen FS, rossing P, Gell NA, et al. Long-term effect of Iisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nepbropatby. Diabetes 1977;46:1182-1188.
7Blood pressure Lowering Treatment Trialist's Conaborarion: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;356:1955 - 1944.
8Messerli FH: Implications of discontinuation of doxazosin arm of ALLHAT: the Antihypertensive and Lipid-Lowering Treatment to Provent Heart Attack Trial. Lancet 2000; 355;863 -864.
9Mogensen CE, Meldam S, Tikkanen I, et al, Randomised controlled trial of dual blockade of renin-angiotension system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan And Lisinopril Microalbuminuria(CALM)Study, BMJ 2000;321 : 1440- 1444.
